The aim of this project is to develop mucus-penetrating particles (MPP) that will improve microbicide delivery for protection against HIV and other STD pathogens such as HSV.
The aim of the R21 phase is to develop MPP to be tested in the R33 phase for protection against HIV in the humanized-BLT-SGlD mouse model. We have completed all of our negotiated milestones. Additionally, we present significant data that support our hypothesis that biodegradable MPP will provide improved protection against HIV and HSV when delivered vaginally once-a-day (non-coitally). We currently have biodegradable MPP that are ready for testing against HSV in our mouse model and against HIV in the humanized-BLT-SClD mouse model in the R33 phase of this project.
|Ensign, Laura M; Cone, Richard; Hanes, Justin (2014) Nanoparticle-based drug delivery to the vagina: a review. J Control Release 190:500-14|
|Yang, Ming; Lai, Samuel K; Yu, Tao et al. (2014) Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J Control Release 192:202-8|
|Ensign, Laura M; Hoen, Timothy E; Maisel, Katharina et al. (2013) Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. Biomaterials 34:6922-9|
|Ensign, Laura M; Henning, Andreas; Schneider, Craig S et al. (2013) Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol Pharm 10:2176-82|
|Xu, Qingguo; Boylan, Nicholas J; Cai, Shutian et al. (2013) Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus. J Control Release 170:279-86|
|Ensign, Laura M; Cone, Richard; Hanes, Justin (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64:557-70|